Tropical Infections
An Introduction to Tropical Infections
Tropical infections result from poverty, poor sanitation, and inadequate health resources, and impose a substantial economic burden on affected countries. Numerous rare and exotic parasitic and bacterial diseases exist. Viral diseases include Ebola, HIV/AIDS, Lassa fever, Marburg virus disease, Rift Valley fever, yellow fever, Zika disease, chikungunya, dengue fever and rabies. Bacteria cause shigellosis, tuberculosis, typhoid fever, typhus, and diseases caused by drug-resistant Gram-negative bacteria. Parasitic diseases include cryptosporidiosis, malaria, Chagas disease, human African trypanosomiasis, leishmaniases, food-borne trematodiases and soli-transmitted helminthiases. Fungal diseases include cryptococcosis and mycetoma. Recent advances have been made in human African trypanosomiasis, tuberculosis and malaria, but many areas remain neglected.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Celebrating the next generation of innovators in infectious diseases Following the success of the 2025 Future Leaders, touchINFECTIOUS DISEASES is delighted to launch nominations for the Future Leaders 2026 initiative. The infectious diseases landscape continues to evolve rapidly, driven by emerging pathogens, ...
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
In this Q&A, Jarod Hanson, Chief Content Office of ProMED, in affiliation with ISID, discuss how the ProMED platform continues to empower clinicians and epidemiologists worldwide, its evolving integration of AI, and how new partnerships aim to extend its reach into low-resource settings to strengthen the global early warning system.
In our inaugural touchINFECTIOUS DISEASES Future Leaders 2025 campaign, we celebrate early-career clinicians and researchers whose innovation, leadership, and curiosity are already shaping better outcomes in patient care, antimicrobial stewardship, and global health.
Bacteriophage therapy uses viruses to infect and kill harmful bacteria, and is re-emerging as a powerful tool in the fight against multidrug-resistant infections. Once overshadowed by the discovery of antibiotics, this highly targeted treatment is now gaining global attention as antibiotic resistance continues to rise. In this Q&A, Ikechukwu Moses (Division of Infectious Diseases, EPM-UNIFESP, São Paulo, Brazil, explores how phage therapy works, its clinical applications, and what’s needed to bring it into mainstream infectious disease care.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
The World Vaccine Congress Washington 2025, 21-24 April 2025, delivered another landmark year, bringing together more than 4,000 global stakeholders from biotechnology, pharmaceuticals, government, academia and the broader global health ecosystem. The event reinforced its standing as an influential and collaborative forum in ...
We are delighted to announce that Dr. Ikechukwu Benjamin Moses has joined the touchINFECTIOUS DISEASES Editorial Board! “I strongly believe that this platform will greatly contribute in promoting science to a broader audience with strong societal impact.” Dr Moses brings ...
The ESCMID Global Congress 2025 brought together world-leading researchers and clinicians to present practice-changing updates in infectious disease management. This article distils five critical insights from interviews and landmark trial results, covering innovations in antimicrobial therapy, fungal infections, resistance surveillance and ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
The US Food and Drug Administration (FDA) has approved the first virus-like particle (VLP) chikungunya vaccine PXVX0317 (VIMKUNYA™), for individuals aged 12 years and older, with Bavarian Nordic recently announcing its commercial launch.1,2 This approval addresses a critical unmet need for ...
Dr Xin Hui Chan’s research focuses on developing equitable therapies for high-threat infectious diseases. She combines clinical trials, evidence synthesis, and modelling to address neglected infections and improve global health outcomes.
Health authorities in the Democratic Republic of the Congo (DRC) are investigating a cluster of unexplained deaths in Ekoto Health Area, Basankusu Health Zone, Equateur Province. The initial report on 9 February 2025 documented 24 deaths in a single village, prompting an investigation ...
Mpox is endemic in the Democratic Republic of the Congo (DRC), with cases rising over the past decade. Children were the most severely affected in the 2023 outbreak, which saw over 14,000 cases and 600 deaths.1 Despite the deployment of the modified vaccinia ...
It was a great pleasure to meet with Tomas Jelinek (The Berlin Center for Travel and Tropical Medicine, Berlin, Germany) to discuss chikungunya virus, its health burden and the unmet needs in its prevention and treatment. Chikungunya virus is spread ...
TouchINFECTIOUSDISEASES had the pleasure of talking to Prof. Dolores Carrer (INIMEC-CONICET-UNC, Córdoba, Argentina) about the current treatments available for cutaneous leishmaniasis and the promising, new generation of treatments on the horizon. Her talk entitled ‘Topical treatments for cutaneous leishmaniasis’ ...
It was lovely to speak with Prof. Dolores Carrer (INIMEC-CONICET-UNC, Córdoba, Argentina) about the current unmet needs in the treatment of cutaneous leishmaniasis. Her talk entitled ‘Topical treatments for cutaneous leishmaniasis’ was presented at the ISNTD d3 Virtual Conference, 24...
It was a delight to be able to speak with Prof. Maria Paola Costi (University of Modena and Reggio Emilia Via Campi, Modena, Italy) about recent discoveries being made in the treatment of visceral leishmaniasis. Her talk entitled ‘Visceral leishmaniasis: ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
